Entities / Company
Biogen.
American multinational biotechnology company
- Reports this week
- 4
- Active events
- 3
- Connections
- 317
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Amundi increased its stake in Biogen shares while Wyoming reduced its holdings on November 12, 2026.Some support1 report
-
Nasdaq adjusted its index on November 11, 2026, removing Biogen and adding Seagate Technology and Western Digital.Some support2 reports
-
Medicare has approved coverage for the drug Leqembi, provided by Biogen and Eisai, under specific conditions.Some support1 report
Earlier this month
-
Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.Some support2 reports
-
Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.Some support1 report
-
Apellis is acquired by Biogen, and Aspaveli receives approval in the European Union.Some support3 reports
-
Frank Bruno signed a petition delivered to the PM as Biogen drug discussions stalled, prompting an MP to accelerate policy talks.Some support1 report
One to three months ago
-
Bank of America upgraded ratings for First Solar and Biogen to buy from hold or underperform.Some support2 reports
-
Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.Some support2 reports
-
Jefferies predicts that Biogen will beat earnings expectations and see a share price move.Some support1 report
-
Biogen and Marker Therapeutics are two healthcare companies that are currently competing for investment.Some support1 report
-
Wyatt Gotbetter was appointed to several senior roles, including President of market access, involving PAREXEL, Cytel, and Biogen.Some support1 report
-
Biogen supplied a drug to the health service (HSE) on September 16, 2026.Some support1 report
-
Biogen, Eisai, and Morgan Stanley announced strategic shifts regarding the LEQEMBI treatment pathway simplification.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Biogen executives spoke at a conference hosted by Wells Fargo on September 12, 2026.Some support1 report
-
Georgia Hart campaigns for the use of a Biogen drug within the UK's National Health Service (NHS) in England, situated within the broader European context.Some support1 report
-
Leaders from Bain & Company and Biogen discussed industry trends at a summit on September 8, 2026.Some support1 report
-
The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).Some support1 report
-
Veeva Systems reported successful Q2 earnings while securing new CRM adoption deals with Eli Lilly and Biogen.Some support1 report
-
HSE and Biogen engaged on August 25, 2026, regarding drug reimbursement for rare diseases.Some support2 reports
-
Biogen provided a substantially improved financial offer on August 25, 2026.Well supported5 reports
-
A US company is manufacturing drugs for Irish citizens, with discussions underway regarding the future role of EU funding models.Some support1 report
-
Michael Ehlers, a former executive at Pfizer and Biogen, is noted, alongside Sanofi backing Formation Bio.Some support1 report
-
Biogen manufactures the drug Skyclarys, which has received approvals from both the EMA and the FDA. The company is also dealing with a high court challenge regarding a delay, while the HSE Drugs Group considers coverage.Some support1 report2 developments inside
Gone quiet
No new reports in 90+ days-
Multiple legal appointments and JD degree completions were reported on August 11, 2026, involving several pharmaceutical companies.Some support1 report
-
AstraZeneca and Biogen are working to meet ambitious revenue targets.Some support1 report
-
Novavax, Nvidia, Biogen, and Amgen are involved in developments regarding specialized infrastructure and their shared status as peers in the therapeutics segment.Some support2 reports
-
Maja Pedersen, who is involved in the current event, previously worked at Biogen.Some support1 report
-
Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.Well supported7 reports1 development inside
-
An article published on July 4, 2026, draws a parallel between the business operations of Nvidia and Biogen.Some support1 report1 development inside
-
Apellis acquisition bolsters the long-term pipeline, with the company aiming to achieve success comparable to Nvidia.Some support1 report
-
AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.Some support2 reports
-
Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.Well supported3 reports1 development inside
-
Biogen stock is traded on Nasdaq and requires filing with the SEC.Well supported4 reports2 developments inside
-
Biogen filed reports with the SEC regarding holdings, while institutional investors increased stock holdings and analyst reports influenced market perception.Some support2 reports
-
The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.Some support4 reports2 developments inside
-
Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.Well supported7 reports
-
Biogen shared efficacy data for the drug Diranersen on July 14, 2026.Some support2 reports
-
Teva Pharmaceutical Industries is competing with major players Bayer, Biogen, and Novartis in the aflibercept biosimilar market.Some support1 report1 development inside
-
Investment purchases span technology and biotech sectors.Some support1 report1 development inside
-
Representatives made various stock trades and analysts updated price targets for tech and biotech firms like Datadog, IBM, and Biogen.Some support2 reports
-
Tariff threats are driving US manufacturing expansion among major pharmaceutical companies like Biogen, Eli Lilly, Roche, and Merck.Well supported4 reports
-
Sanofi, Scribe Therapeutics, and Biogen are partnering on ALS gene therapy research, seeking a second research deal and initial public offering on Nasdaq.Some support2 reports
-
Australian clinical trial models are attracting companies like Biogen as they eye European markets under FDA oversight.Some support1 report
-
Freedom Capital upgraded Biogen shares, and MarketBeat reported the consensus rating for the company.Some support7 reports
-
Biogen highlights continued progress in its portfolio, including research into tau-targeting ASO for Alzheimer's.Some support2 reports
-
Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.Some support3 reports2 developments inside
-
Biogen is associated with Cambridge, Mass.Some support6 reports
-
Biogen is expanding its portfolio through an acquisition of RayThera Inc., adding valuable immunology assets to its holdings.Well supported8 reports
-
Biogen enters into an exclusive license agreement for ALT-B4 technology with ALTEOGEN Inc., with operations conducted in the PRC and internationally.Some support1 report
-
An investigation has been announced in New York City involving the company Biogen.Some support1 report
-
Sinclair and Biogen were analyzed as low-volatility stocks on July 11, 2025.Some support1 report
-
Biogen shipped Leqembi to China for inventory optimization.Some support1 report
-
Bayer and Biogen announced they were both adopting .med TLDs on August 12, 2025.Some support1 report
-
Biogen, Mitsubishi Tanabe Pharma, and Ionis Pharmaceuticals are highlighted as being at the forefront of innovation in the field of ALS.Some support1 report
-
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Well supported4 reports12 developments inside
-
Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.Some support3 reports
-
FDA approved BYOOVIZ as the first ophthalmology biosimilar, leading to a commercial rights transfer from Biogen to Harrow.Some support4 reports
-
A gene therapy for Friedreich ataxia has been designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.Speculative1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Biogen
Events traced to Biogen, step by step, newest first- Biogen's partnership may be reviewed as Royalty Pharma expands biotech investmentsBiogen's R&D funding partnership may face review as Royalty Pharma expands biotech focusPossible
- Liquidia settlement may shift competitive dynamics for BiogenBiogen may face a shifting competitive landscape following Liquidia's settlementPossible
Around Biogen this week
News at the entities that move Biogen most-
Freedom Capital TransactionalFreedom Capital lowered its rating for Genie Energy, while MarketBeat provided average rating data.Moves Biogen
-
FDA StructuralFDA approval coincided with Donald Trump's press conference on November 11, 2026.Moves Biogen
-
Veeva Systems OperationalVeeva Systems and Definitive Healthcare are being compared as healthcare companies.Moves Biogen
-
Donald Trump OperationalGermany deploys missiles into Russian territory and strengthens its arsenal amid European defense alignment.Moves Biogen
-
Hoffmann-La Roche StructuralOmar Khwaja, a Fellow of the Royal College of Physicians, leads clinical research at Cancer Research UK.Moves Biogen
-
Morgan Stanley OperationalFinancial firms, including RBC, Morgan Stanley, and TD Cowen, issued rating and holding updates on Vir Biotechnology.Moves Biogen
Connections
The 40 strongest of 317, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Eisai Structural
Biogen and Eisai are formally partnered for the joint development, commercialization, and revenue sharing of the Alzheimer's drug Leqembi.
-
Reata Pharmaceuticals Structural
Biogen acquired Reata Pharmaceuticals, establishing Reata as a subsidiary of Biogen.
-
Freedom Capital Transactional
Freedom Capital upgraded Biogen shares/rating to strong-buy in a recorded market action.
-
Veeva Systems Operational
Biogen utilizes Veeva's Vault CRM platform for its ongoing operational needs.
-
BioArctic Structural
BioArctic provided foundational IP that led to a current joint venture with Biogen, evidenced by shared financial reporting.
-
FDA Structural
The FDA functions as the mandatory regulatory body responsible for approving and overseeing Biogen's drug development and market access.
-
Sage Therapeutics (United States) Operational
The companies maintain an ongoing operational partnership for Zurzuvae commercialization while simultaneously engaging in strategic competition and M&A attempts.
-
Royalty Pharma Structural
Royalty Pharma receives payments and holds royalty rights on Biogen's products, supplemented by an ongoing R&D funding partnership.
Show all 40 connections
-
Michael McDonnell Structural
Michael McDonnell held the role of Chief Financial Officer for Biogen.
-
Amundi Transactional
Amundi has engaged in significant, fluctuating investment activity regarding Biogen shares.
-
AstraZeneca Operational
The two companies are actively competing in the market, facing pressure to meet ambitious revenue targets.
-
Donald Trump Operational
Political uncertainty and tariff threats drive Biogen's operational decisions, specifically manufacturing expansion.
-
Regeneron Pharmaceuticals Operational
Regeneron and Biogen are active competitors across ophthalmology, immunology, and oncology therapeutic areas.
-
HSE Transactional
HSE and Biogen are engaged in ongoing negotiations regarding drug access, supply, and financial reimbursement for rare disease treatments.
-
Ivana Structural
Ivana gained professional experience while employed by Biogen.
-
SEC Structural
Biogen is subject to mandatory regulatory oversight and reporting requirements by the SEC.
-
Nasdaq Structural
Biogen is a company formally listed and traded on the Nasdaq stock exchange, a relationship that was later terminated.
-
Securities and Exchange Commission Structural
Biogen operates under the mandatory oversight and reporting requirements of the Securities and Exchange Commission.
-
Hoffmann-La Roche Structural
Biogen receives royalties from drugs developed by Hoffmann-La Roche.
-
United Therapeutics Operational
The two companies actively compete in the market as therapeutics stocks, with market performance and results influencing the other's standing.
-
Morgan Stanley Operational
Morgan Stanley actively tracks Biogen and influences its market valuation through strategic reports and target price increases.
-
Bank of America Operational
Bank of America actively tracks and issues investment ratings and recommendations regarding Biogen.
-
Invesco Structural
Invesco maintains a large, ongoing investment position in Biogen.
-
Michael Ehlers Structural
Michael Ehlers held a former executive position at Biogen.
-
Health Service Executive Transactional
HSE negotiated funding approval and approved reimbursement for treatments provided by Biogen.
-
representative Transactional
Representative purchased shares of Biogen in a historical transaction.
-
Teva Pharmaceutical Industries Ltd. Operational
Biogen and Teva are direct competitors in the aflibercept biosimilar market.
-
MarketBeat Mentioned together
MarketBeat consistently reports and tracks financial data and consensus ratings for Biogen.
-
Merck Operational
Biogen and Merck are major pharmaceutical companies that share strategic investments in US manufacturing amid tariff risks.
-
Novavax Operational
The evidence indicates that both companies are direct competitors operating as peers within the therapeutics segment.
-
Mizuho Transactional
Mizuho analysts raised their price target recommendation for Biogen, signaling market valuation.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides investment ratings and market coverage on Biogen.
-
Moderna Operational
Moderna and Biogen are competitors operating in the therapeutics segment, with evidence of personnel exchange between the two companies.
-
Gilead Sciences Operational
The two companies are recognized as peers and actively compete within the therapeutics market.
-
Novartis Operational
The companies actively compete in the health and wellness market, with their treatments being compared in efficacy studies.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis and price targets for Biogen stock.
-
Wells Fargo Mentioned together
Wells Fargo analysts provided market coverage, including increasing Biogen's price objective.
-
Truist Financial Operational
Truist Financial upgraded Biogen's rating and target price.
-
Mike Structural
Mike served as the Chief Financial Officer of Biogen Inc.
-
Ionis Pharmaceuticals Operational
Ionis Pharmaceuticals and Biogen maintain an active operational partnership for drug development and clinical trials.
History
Events by the month they beganNovember 2026
4 events- Amundi increased its stake in Biogen shares while Wyoming reduced its holdings on November 12, 2026.
- Nasdaq adjusted its index on November 11, 2026, removing Biogen and adding Seagate Technology and Western Digital.
- Medicare has approved coverage for the drug Leqembi, provided by Biogen and Eisai, under specific conditions.
- Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.
October 2026
5 events- Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.
- Frank Bruno signed a petition delivered to the PM as Biogen drug discussions stalled, prompting an MP to accelerate policy talks.
- Bank of America upgraded ratings for First Solar and Biogen to buy from hold or underperform.
- Jefferies predicts that Biogen will beat earnings expectations and see a share price move.
- Biogen and Marker Therapeutics are two healthcare companies that are currently competing for investment.
September 2026
8 events- Wyatt Gotbetter was appointed to several senior roles, including President of market access, involving PAREXEL, Cytel, and Biogen.
- Biogen supplied a drug to the health service (HSE) on September 16, 2026.
- Biogen, Eisai, and Morgan Stanley announced strategic shifts regarding the LEQEMBI treatment pathway simplification.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Biogen executives spoke at a conference hosted by Wells Fargo on September 12, 2026.
- Georgia Hart campaigns for the use of a Biogen drug within the UK's National Health Service (NHS) in England, situated within the broader European context.
- Leaders from Bain & Company and Biogen discussed industry trends at a summit on September 8, 2026.
- The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).
Show 3 earlier months
August 2026
10 events- Veeva Systems reported successful Q2 earnings while securing new CRM adoption deals with Eli Lilly and Biogen.
- HSE and Biogen engaged on August 25, 2026, regarding drug reimbursement for rare diseases.
- Biogen provided a substantially improved financial offer on August 25, 2026.
- A US company is manufacturing drugs for Irish citizens, with discussions underway regarding the future role of EU funding models.
- Michael Ehlers, a former executive at Pfizer and Biogen, is noted, alongside Sanofi backing Formation Bio.
- Biogen manufactures the drug Skyclarys, which has received approvals from both the EMA and the FDA. The company is also dealing with a high court challenge regarding a delay, while the HSE Drugs Group considers coverage.
- Multiple legal appointments and JD degree completions were reported on August 11, 2026, involving several pharmaceutical companies.
- AstraZeneca and Biogen are working to meet ambitious revenue targets.
- Novavax, Nvidia, Biogen, and Amgen are involved in developments regarding specialized infrastructure and their shared status as peers in the therapeutics segment.
- Maja Pedersen, who is involved in the current event, previously worked at Biogen.
July 2026
10 events- Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.
- An article published on July 4, 2026, draws a parallel between the business operations of Nvidia and Biogen.
- Apellis acquisition bolsters the long-term pipeline, with the company aiming to achieve success comparable to Nvidia.
- AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.
- Biogen filed reports with the SEC regarding holdings, while institutional investors increased stock holdings and analyst reports influenced market perception.
- Biogen shared efficacy data for the drug Diranersen on July 14, 2026.
- Representatives made various stock trades and analysts updated price targets for tech and biotech firms like Datadog, IBM, and Biogen.
- Sanofi, Scribe Therapeutics, and Biogen are partnering on ALS gene therapy research, seeking a second research deal and initial public offering on Nasdaq.
- Australian clinical trial models are attracting companies like Biogen as they eye European markets under FDA oversight.
- Freedom Capital upgraded Biogen shares, and MarketBeat reported the consensus rating for the company.
June 2026
23 events- Apellis is acquired by Biogen, and Aspaveli receives approval in the European Union.
- Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.
- Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.
- Biogen stock is traded on Nasdaq and requires filing with the SEC.
- The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
- Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.
- Teva Pharmaceutical Industries is competing with major players Bayer, Biogen, and Novartis in the aflibercept biosimilar market.
- Investment purchases span technology and biotech sectors.
- Tariff threats are driving US manufacturing expansion among major pharmaceutical companies like Biogen, Eli Lilly, Roche, and Merck.
- Biogen highlights continued progress in its portfolio, including research into tau-targeting ASO for Alzheimer's.
- Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.
- Biogen is associated with Cambridge, Mass.
- Biogen is expanding its portfolio through an acquisition of RayThera Inc., adding valuable immunology assets to its holdings.
- Biogen enters into an exclusive license agreement for ALT-B4 technology with ALTEOGEN Inc., with operations conducted in the PRC and internationally.
- An investigation has been announced in New York City involving the company Biogen.
- Sinclair and Biogen were analyzed as low-volatility stocks on July 11, 2025.
- Biogen shipped Leqembi to China for inventory optimization.
- Bayer and Biogen announced they were both adopting .med TLDs on August 12, 2025.
- Biogen, Mitsubishi Tanabe Pharma, and Ionis Pharmaceuticals are highlighted as being at the forefront of innovation in the field of ALS.
- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.
- FDA approved BYOOVIZ as the first ophthalmology biosimilar, leading to a commercial rights transfer from Biogen to Harrow.
- A gene therapy for Friedreich ataxia has been designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.